The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.12), FiscalAI reports. According to data from MarketBeat.com, Immunovant has an average rating of “Moderate Buy” and a consensus price target of $44.00. The stock was sold at an average price of $33.51, for a total value of $7,437,578.01. The shares were sold at an average price of $38.31, for a total transaction of $678,623.34. Insiders have sold a total of 324,810 shares of company stock valued at $11,350,166 over the last 90 days.